{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:49:19Z","timestamp":1793119759756,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["765007-RES01"],"award-info":[{"award-number":["765007-RES01"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vhri.2024.101011","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:45:05Z","timestamp":1717749905000},"page":"101011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation"],"prefix":"10.1016","volume":"43","author":[{"given":"Piyameth","family":"Dilokthornsakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratree","family":"Sawangjit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisit","family":"Tangkijvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneerat","family":"Chayanupatkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unchalee","family":"Permsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2024.101011_bib1","unstructured":"Akinyemiju T, Abera S, et\u00a0al. The Burden of Primary Liver Cancer and Underlying Etiologies From. Global burden of disease liver Cancer C. JAMA Oncol 2017. 2015;3: 1683-91:1990-2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study."},{"issue":"28","key":"10.1016\/j.vhri.2024.101011_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection - worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vhri.2024.101011_bib3","series-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections. Accountability for the Global Health Sector Strategies 2016-2021: Actions for Impact","year":"2021"},{"issue":"4","key":"10.1016\/j.vhri.2024.101011_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.vhri.2024.101011_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.vhri.2024.101011_bib6","series-title":"Thailand practice guideline for management of chronic hepatitis B and C 2015","year":"2015"},{"issue":"1","key":"10.1016\/j.vhri.2024.101011_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-022-09413-7","article-title":"Risk of hepatocellular carcinoma in antiviral treatment-na\u00efve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2024.101011_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vhri.2024.101011_bib9","article-title":"Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation","volume":"35","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"10.1016\/j.vhri.2024.101011_bib10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/14737167.2023.2231636","article-title":"Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis","volume":"23","author":"Dilokthornsakul","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.vhri.2024.101011_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40258-022-00719-y","article-title":"Economic evaluation of oral Nucleos(t)ide analogues for patients with chronic hepatitis B in Thailand","volume":"20","author":"Dilokthornsakul","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.vhri.2024.101011_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.vhri.2024.101011_bib15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.vhri.2024.101011_bib16","first-page":"406","article-title":"Health-related quality of life as measured by EQ-5D and TFLIC-2 in liver cancer patients","volume":"70","author":"Wongphan","year":"2018","journal-title":"Siriraj Med J"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/v15030724","article-title":"A\u00a0novel and simplified score for determining treatment eligibility for patients with chronic hepatitis B","volume":"15","author":"Geeratragool","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.vhri.2024.101011_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","article-title":"Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vhri.2024.101011_bib20","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","article-title":"Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis","volume":"27","author":"Veenstra","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.vhri.2024.101011_bib21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.vhri.2024.101011_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40273-018-0736-0","article-title":"Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand","volume":"37","author":"Chongmelaxme","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"30","key":"10.1016\/j.vhri.2024.101011_bib23","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.18632\/oncotarget.25108","article-title":"Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0\/A hepatocellular carcinoma","volume":"9","author":"Ishikawa","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"Surgery versus radiofrequency ablation for Small Hepatocellular Carcinoma: a randomized controlled trial (SURF Trial)","volume":"11","author":"Takayama","year":"2022","journal-title":"Liver Cancer"},{"issue":"34","key":"10.1016\/j.vhri.2024.101011_bib25","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.3748\/wjg.v22.i34.7806","article-title":"Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area","volume":"22","author":"Ungtrakul","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101011_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lt.24360","article-title":"Intention to treat outcome of T1 hepatocellular carcinoma with the \u201cwait and not ablate\u201d approach until meeting T2 criteria for liver transplant listing","volume":"22","author":"Mehta","year":"2016","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.vhri.2024.101011_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3350\/cmh.2018.0072","article-title":"Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization","volume":"25","author":"Bannangkoon","year":"2019","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"10.1016\/j.vhri.2024.101011_bib28","first-page":"1029","article-title":"Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy","volume":"52","author":"Shim","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.vhri.2024.101011_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5604\/01.3001.0009.8597","article-title":"Surveillance for hepatocellular carcinoma reduces mortality: an inverse probability of treatment weighted analysis","volume":"16","author":"Chaiteerakij","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.vhri.2024.101011_bib30","unstructured":"Strategy and Planning Division. Ministry of Public Health. Public Health Statistic A.D.2020. Nonthaburi, Thailand: Ministry of Public Health; 2021."},{"issue":"4","key":"10.1016\/j.vhri.2024.101011_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.aidm.2013.12.001","article-title":"Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization","volume":"1","author":"Lin","year":"2014","journal-title":"Adv Dig Med"},{"issue":"1","key":"10.1016\/j.vhri.2024.101011_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.510290145","article-title":"Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials","volume":"29","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.vhri.2024.101011_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic hepatitis B infection","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.vhri.2024.101011_bib34","series-title":"1st ed Nontahburi, Thailand: The graphico system","article-title":"Guidelines for Health Technology Assessment in Thailand","author":"Chaikledkaew","year":"2009"},{"issue":"Suppl 5","key":"10.1016\/j.vhri.2024.101011_bib35","first-page":"S4","article-title":"Guidelines for health technology assessment in Thailand (second edition)-the development process","volume":"97","author":"Chaikledkaew","year":"2014","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.vhri.2024.101011_bib36","author":"Riewpaiboon"},{"key":"10.1016\/j.vhri.2024.101011_bib37","first-page":"908","article-title":"Economic evaluation and budget impact analysis of liver transplantation among Thai adults in universal health insurance coverage in Thailand","volume":"25","author":"Pachanee","year":"2016","journal-title":"J\u00a0Health Sci"},{"key":"10.1016\/j.vhri.2024.101011_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vhri.2013.09.002","article-title":"Resource utilization and direct medical costs of chronic hepatitis C in Thailand: a heavy but manageable economic burden","volume":"3","author":"Thongsawat","year":"2014","journal-title":"Value Health Reg Issues"},{"issue":"20","key":"10.1016\/j.vhri.2024.101011_bib39","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.7314\/APJCP.2014.15.20.8993","article-title":"Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients","volume":"15","author":"Sangmala","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.vhri.2024.101011_bib40","series-title":"Ministry of Public Health. Median Price for Medications","year":"2022"},{"key":"10.1016\/j.vhri.2024.101011_bib41","series-title":"Health Service Charges for Health Centers Under the Ministry of Public Health for Thai 2562 B.C","year":"2019"},{"key":"10.1016\/j.vhri.2024.101011_bib42","series-title":"Consumer price index","year":"2021"},{"key":"10.1016\/j.vhri.2024.101011_bib43","series-title":"Exchange Rates for Commercial Banks","year":"2023"},{"key":"10.1016\/j.vhri.2024.101011_bib44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2016.08.017","article-title":"Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis","volume":"51","author":"Leroi","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vhri.2024.101011_bib45","first-page":"537","article-title":"Clinical effect of tenofovir alafenamide fumarate on chronic hepatitis B patients with low viral load after entecavir treatment","volume":"38","author":"Cheng","year":"2022","journal-title":"J\u00a0Clin Hepatol"},{"issue":"5","key":"10.1016\/j.vhri.2024.101011_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00535-020-01680-0","article-title":"Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review","volume":"55","author":"de Fraga","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.vhri.2024.101011_bib47","article-title":"Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2023","journal-title":"JHEP Rep"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400044X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992400044X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:33:25Z","timestamp":1762605205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992400044X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"alternative-id":["S221210992400044X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101011","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simplified Chronic Hepatitis B Antiviral Initiation Criteria in Thailand: An Economic Evaluation","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101011"}}